Although atezolizumab or durvalumab in combination with chemotherapy has been suggested as a first-line regimen for the treatment of extensive-stage SCLC, the anti-PD-L1 ICIs are not widely covered by public health insurance policies in most countries, due to concerns about cost-effectiveness [16,17]. This evidence concerns the gene CD274 and small cell lung carcinoma.